On Drug Prices, Harris Pushes for Deeper Cuts While Trump Offers Few Specifics

Published On Oct 8, 2024, 1:07 PM

In the lead-up to the November election, Vice President Kamala Harris is promising to expand President Biden’s drug pricing policies, including limits on insulin costs and out-of-pocket expenses for older citizens. Meanwhile, former President Donald Trump has not laid out a clear plan on drug pricing, having recently changed his stance on price controls that would align U.S. drug prices with those in other countries. While drug pricing is not a central campaign issue, the outcome of the election could significantly impact policies affecting pharmaceutical costs and negotiations for Medicare.

Read full article

Stock Forecasts

AI prediction results, not representative of any investment advice.

PFE View PFE chart on TradingView

Negative

If Harris wins and expands drug pricing policies, companies producing drugs subject to these negotiations could see a reduction in revenues, potentially affecting their stock prices negatively. Conversely, a lack of major reforms under Trump could stabilize or even boost these stocks, considering his previous ties to the pharmaceutical lobby.

XBI View XBI chart on TradingView

Positive

Companies focused on negotiating drug prices or providing cheaper medications could see a positive response in their stock as the public sentiment combines with potential legislative support from Harris's plan.

On Drug Prices, Harris Pushes for Deeper Cuts While Trump Offers Few Specifics

Stock Forecasts

PFE View PFE chart on TradingView

XBI View XBI chart on TradingView

Related News